Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
|Articles|December 31, 2021
Daily Medication Pearl: Avapro (Irbesartan)
Author(s)Saro Arakelians, PharmD
Avapro (Irbesartan) is indicated for the treatment of hypertension and used to lower blood pressure.
Advertisement
Medication Pearl of the Day: Avapro (Irbesartan)
Indication: Avapro (Irbesartan)is an angiotensin II receptor blocker indicated for the treatment of hypertension and used to lower blood pressure.
Insight:
- Dosing: Avapro (Irbesartan) can be taken at 150 to 300 mg daily.
- Dosage forms: Avapro (Irbesartan) comes in tablet forms at 75 mg, 150 mg, and 300 mg.
- Adverse events (AEs): In type 2 diabetic patients, the most common AE experienced by patients on Avapro (Irbesartan) is nephropathy, or the deterioration of kidney function. The AEs that were found to be more frequent than placebo were hyperkalemia dizziness, orthostatic dizziness, and orthostatic hypotension.
- Mechanism of action: Avapro (Irbesartan) blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the angiotensin II receptor type 1 found in many tissues.
- Manufacturer: Lupin Pharma
Source:
Advertisement
Related to this article
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Ramantamig's 93.6% ORR and Outpatient CRS Control
2
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
After 180 Years, Multiple Myeloma Gets a Definition of Cure
5